Aarti Pharmalabs Limited — Investor Meet, 16-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Aarti Pharmalabs reported Q3 FY26 revenue of INR425 Cr and PAT of INR44 Cr, declaring an interim dividend of INR1.5 per share. Q3 results were impacted by INR49 Cr of goods in transit (INR19 Cr PBT), expected to be booked in Q4.

The CDMO segment (12% revenue) has a strong pipeline with 40 commercial projects, with management expecting future growth. API & Intermediates (39%) faces margin pressure, but new launches and debottlenecking are planned for FY27. Xanthine Derivatives (49%) is expanding capacity and anticipates better pricing due to China's rebate withdrawal.

Initial production challenges at the new Atali plant are expected to resolve by Q4 end. Management projects FY26 EBITDA to be largely in line with last year due to Atali delays and API softness, but remains confident in mid-to-long term growth.